JAGSNPHARM

** Shares of Jagsonpal Pharmaceuticals JGSN.NS slide as much 4.4% to 210.03 rupees, last down 1.1%

** Drugmaker gets U.S. FDA warning letter related to drug listing, establishment registration after plant inspection

** Co estimates sales hit worth 35 mln rupees ($403,960) so far in current fiscal year

** Stock down 10% YTD, it logged five straight years of gains till 2024

($1 = 86.6420 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Feb 21 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - RECEIVES WARNING LETTER FROM USFDA

• JAGSONPAL PHARMACEUTICALS LTD - USFDA CITES CGMP DEVIATION, REGISTRATION, AND LISTING VIOLATION

• JAGSONPAL PHARMACEUTICALS: USFDA WARNING REGARDING OBSERVATIONS DURING INSPECTION OF CONTRACT MANUFACTURING FACILITY OF JAGSONPAL

• JAGSONPAL PHARMACEUTICALS - FINANCIAL IMPACT INCLUDES SALE OF 35 MILLION RUPEES

Source text: ID:nBSEbDdYHY

Further company coverage: JGSN.NS

(([email protected];))

Feb 5 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• NAMES SACHIN JAIN AS CHIEF FINANCIAL OFFICER

Source text: [ID:]

Further company coverage: JGSN.NS

(([email protected];;))

** Jagsonpal Pharmaceuticals JGSN.NS jumps 7% to 244 rupees

** Co's Q3 profit jumps nearly three-fold, helped by strong sales of gynaecology products

** About 900,000 shares traded in stock's most active session since Dec. 3, 2024

** JGSN marginally up YTD; had risen 57% in 2024

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Nov 22 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS - CFO ASHISH LAKHOTIA RESIGNS

Source text: ID:nBSE5Z828b

Further company coverage: JGSN.NS

(([email protected];))

Nov 19 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS - GOT 410 MILLION RUPEES TOWARDS SALE OF CO'S FARIDABAD FACILITY

Source text: ID:nNSE6311kK

Further company coverage: JGSN.NS

(([email protected];))

** Shares of Jagsonpal Pharmaceuticals Ltd JGSN.NS rise as much as 5.6% to 499.80 rupees

** Pharma co reported 53.4% y/y rise in Q2 profit to 114.6 mln rupees ($1.4 mln); rev jumped 29.2%

** Board also approved sub division of shares

** Stock on track to gain for 5th straight month; gained 18.3% so far this month

** More than 163,000 shares traded as of 10:13 a.m. IST, vs their 30-day moving avg of 89,502 shares

** JGSN last up 3.5%, adding to YTD gains of 26% so far

($1 = 84.0650 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Oct 23 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - APPROVED SUB-DIVISION OF SHARES

Source text for Eikon: ID:nBSE1mV11V

Further company coverage: JGSN.NS

(([email protected];))

May 24 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• LAUNCHES MEMUP, A BIOIDENTICAL HORMONE REPLACEMENT THERAPY

Source text for Eikon: ID:nBSE7hQtsH

Further company coverage: JGSN.NS

(([email protected];))

March 8 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• LAUNCHES QUEEZY-ER®

• QUEEZY-ER® PROVIDING RELIEF FROM NAUSEA AND VOMITING IN PREGNANCY

Source text for Eikon: [ID:]

Further company coverage: JGSN.NS

(([email protected];))

May 23 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• DIVIDEND OF 5 RUPEES PER SHARE

• MARCH-QUARTER NET PROFIT 56 MILLION RUPEES VERSUS PROFIT 3.1 MILLION RUPEES

• MARCH-QUARTER REVENUE FROM OPERATIONS 554.5 MILLION RUPEES VERSUS 512.3 MILLION RUPEES

Source text for Eikon: ID:nBSE7Q3W2k

Further company coverage: JGSN.NS

(([email protected];))